Human Oncology & Pathogenesis Program

The Ping Chi Lab

Ping Chi, MD, PhD

Member, Human Oncology and Pathogenesis Program

Professor

It is well recognized that the cellular context contributes to susceptibility to oncogenic transformation mediated by different “driver” oncogenes. The focus of our laboratory is to discover and understand the critical genetic and epigenetic factors that determine the cellular-context-dependent oncogenesis in distinct cancer types, with a primary focus on sarcoma and melanoma. We use multimodality approaches, including transcriptome analyses, epigenome mapping, and gene-expression-based high-throughput screens, as well as murine models to understand the mechanisms of pathogenesis and to develop biomarkers and targeted therapies based on insight into disease pathogenesis.

View Lab Overview

Featured News

Event

2017 MSK Convocation and Commencement Ceremony Celebrates Distinguished Scientists and Young Scholars

Degrees were presented and awards were given at the 38th annual ceremony held on May 18.

In the Lab

Molecular Studies Provide New Clues about Rare Soft Tissue Sarcoma

Genetic analysis reveals biomarkers and possible drug targets for malignant peripheral nerve sheath tumors.

Announcement

Geoffrey Beene Rock Stars of Science™ Campaign Features Memorial Sloan Kettering Researchers

The initiative, focused on investigators from Memorial Sloan Kettering’s Geoffrey Beene Cancer Research Center, highlights the critical need for funding scientific research.

View All Featured News

Publications Highlights

Patel AJ, Warda S, Maag JLV, Misra R, Miranda-Roman MA, Pachai MR, Lee CJ, Li D, Wang N, Bayshtok G, Fishinevich E, Meng Y, Wong EWP, Yan J, Giff E, Pappalardi MB, McCabe MT, Fletcher JA, Rudin CM, Chandarlapaty S, Scandura JM, Koche RP, Glass JL, Antonescu CR, Zheng D, Chen Y*, Chi P*. PRC2 Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1 Targeted Therapy via Enhanced Viral Mimicry. Cancer Discovery. 2022 Jul 5:cd.21.1671. doi: 10.1158/2159-8290.CD-21-1671. Online ahead of print. PMID: 35789380; Featured in “In the Spotlight”.

Yan J, Chen Y, Patel AJ, Warda S, Lee CJ, Nixon BG, Wong EWP, Miranda-Román MA, Yang N, Wang Y, Pachai MR, Sher J, Giff E, Tang F, Khurana E, Singer S, Liu Y, Galbo PM Jr, Maag JL, Koche RP, Zheng D, Antonescu C, Deng L, Li M, Chen Y*, Chi P*. Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic therapeutic viruses. Journal of Clinical Investigation. 2022 Jul 19:e153437. doi: 10.1172/JCI153437. Epub ahead of print. PMID: 35852856.

Chi P*, Qin LX, Nguyen B, Kelly CM, D’Angelo SP, Dickson MA, Gounder MM, Keohan ML, Movva S, Nacev BA, Rosenbaum E, Thornton KA, Crago AM, Yoon S, Ulaner G, Yeh R, Martindale M, Phelan HT, Biniakewitz MD, Warda S, Lee CJ, Berger MF, Schultz ND, Singer S, Hwang S, Chen Y, Antonescu CR, Tap WD. Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor. Journal of Clinical Oncology. 2022;40(9):997-1008. PMCID: PMC8937014.

Chi P*, Qin LX, Camacho N, Kelly CM, D’Angelo SP, Dickson MA, Gounder MM, Keohan ML, Movva S, Nacev BA, Rosenbaum E, Thornton KA, Crago AM, Francis JH, Martindale M, Phelan HT, Biniakewitz MD, Lee CJ, Singer S, Hwang S, Berger MF, Chen Y, Antonescu CR, Tap WD*. Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors. Clinical Cancer Research. 2022;28(8):1507-1517. PMCID: PMC9012681.

Tang F, Xu D, Wang S, Wong CK, Martinez-Fundichely A, Lee CJ, Cohen S, Park J, Hill CE, Eng K, Bareja R, Han T, Liu EM, Palladino A, Di W, Gao D, Abida W, Beg S, Puca L, Meneses M, de Stanchina E, Berger MF, Gopalan A, Dow LE, Mosquera JM, Beltran H, Sternberg CN, Chi P, Scher HI, Sboner A, Chen Y, Khurana E. Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets. Science. 2022; 376(6596):eabe1505. PMCID: PMC9299269.

View All Publications

People

Ping Chi, MD, PhD

Member, Human Oncology and Pathogenesis Program

Professor

Physician-scientist Ping Chi studies genetic and epigenetic mechanisms of transcriptional regulation by oncogenic factors in GIST, MPNST, melanoma and other solid tumors.
MD, Weill Cornell Medical College
PhD, The Rockefeller University

View physician profile: Physician profile

Members

Vaishnavi Reeya Callychurn
Research Technician

Elissa Wai Wong Pung — Elissa Wai Pung Wong
Senior Research Scientist

Lab Alumni

Gabriella Bayshtok

Research Technician

Dan Li, Research Fellow — Dan Li
Research Fellow

Miguel Miranda-Roman — Miguel A. Miranda-Roman
Postdoctoral Fellow at Boehringer Ingelheim in Ridgefield, CT

Sewit Teckie
Radiation Oncology Resident

Lab Affiliations

Achievements

Kimmel Scholar Award, Sidney Kimmel Foundation (2012)
Research Grant, Sarcoma Foundation of America (2012)
Grant, GIST Cancer Awareness Foundation (2012)
Director’s New Innovator Award, National Institutes of Health (2012)
Clinical Scientist Development Award, National Instistutes of Health (2011)

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Career Opportunities

Apply now

Get in Touch

646-888-3349

Lab Phone

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Ping Chi discloses the following relationships and financial interests:

Boxer Capital, LLC
Professional Services and Activities
Deciphera
Professional Services and Activities

Ningbo NewBay Medical Technology Co., Ltd.
Professional Services and Activities

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures